Published on 01/12/2025

Storyboarding Ongoing Review for Inspections

In the complex field of pharmaceutical operations, the ongoing review is an essential process that ensures compliance with regulatory expectations while maintaining the highest levels of quality. This tutorial guide serves as a comprehensive roadmap for pharmaceutical professionals engaged in supplier, CMO/CDMO oversight, and technology provider management. It outlines a structured approach to evaluate and enhance the ongoing review processes, crucial for successful inspections from regulatory authorities such as the FDA, EMA, and MHRA.

1. Introduction to Ongoing Review

The ongoing review process is a critical element of pharmaceutical quality systems as delineated in ICH Q10. It supports consistent product quality by monitoring and assessing various operational aspects, including supplier qualifications and quality agreement clauses. Understanding this process is crucial for pharmaceutical professionals whose roles encompass compliance, quality assurance, and risk management.

As drug products evolve through development and production phases, the ongoing review allows for the detection of potential deviations that could impact product quality or regulatory compliance. This process not only surfaces issues but also emphasizes the need for a proactive strategy incorporating risk scoring methods to guide decision-making.

2. Establishing a Risk-Based Approach

A comprehensive ongoing review starts with establishing a risk-based approach. Risk management is integral to ensuring that suppliers meet their product quality obligations. This section outlines the key elements necessary to develop a risk-based framework for ongoing supplier and CMO/CDMO oversight.

2.1 Defining Risk

Risk in pharmaceutical terms is the combination of the probability of occurrence of harm and the consequences of that harm. This definition is encompassed in the ICH Q9 guidelines, which advocate for a systematic approach to identify, assess, control, and communicate risk. Understanding risk requires incorporating various dimensions, such as:

• Severity of Impact: Identifying the potential impact on product quality and patient safety.
• Likelihood of Occurrence: Evaluating how often a risk is likely to happen based on historical data and supplier performance.
• Ability to Detect: Assessing the current quality controls in place to detect the risk before it affects product quality.

2.2 Risk Scoring Methodology

The next step involves creating a risk scoring methodology. This typically includes developing a scoring system that quantifies the perceived risk based on the defined elements above. Each supplier or CMO/CDMO can be scored on a scale (e.g., 1-5) across the parameters of severity, likelihood, and detection ability. The overall risk score can help prioritize the areas needing ongoing review and further risk mitigation efforts.

3. Supplier Qualification and Quality Agreement Clauses

An effective ongoing review process is built on thorough supplier qualifications and comprehensive quality agreements. This section discusses essential quality agreement clauses that should be included in any contract with suppliers and CMOs/CDMOs for effective oversight.

3.1 Supplier Qualification Process

The supplier qualification process is vital in establishing the foundation of a robust ongoing review. This should include:

• Pre-assessment: Evaluate potential suppliers’ capabilities related to quality, compliance, and reliability.
• Audit and Evaluation: Conduct vendor audits to thoroughly assess quality management systems and processes.
• Performance Metrics: Define key performance indicators (KPIs) to monitor ongoing supplier performance against quality standards.

3.2 Essential Quality Agreement Clauses

Beyond supplier qualification, quality agreements must delineate clear responsibilities and expectations. Key clauses to include are:

• Product Specifications: Clearly outline product quality specifications and regulatory standards.
• Responsibilities: Decomposing the roles and responsibilities between parties in terms of quality assurance, risk management, and complaint handling.
• Change Notification: Stipulating mandatory change notification clauses for any adjustments in suppliers’ processes, materials, or equipment.

These clauses play a significant role in ensuring that any ongoing review adheres to predetermined quality standards and facilitates compliance under regulations such as 21 CFR Part 11.

4. Validation Deliverables in Ongoing Review

Validation deliverables are essential in the ongoing review of suppliers and CMO/CDMOs, ensuring that all processes remain compliant and effective. This section highlights the critical validation activities that must align with ongoing reviews.

4.1 Understanding Validation Deliverables

Validation deliverables include documents created throughout the validation lifecycle that substantiate that processes, systems, and equipment meet the required specifications and quality standards. Key deliverables include:

• Validation Plans: Outlining the scope, approach, and validation schedule for processes and systems.
• Risk Assessments: Incorporating risk analysis into the validation strategy to allow for flexibility based on supplier metrics.
• Protocols and Reports: Documenting all validation testing, results, and any deviations or corrective actions taken.

4.2 The Role of Method Transfer Equivalence

Method transfer equivalence is especially important when transitioning analytical methods between laboratories or suppliers. Ensuring that the methods produce comparable results irrespective of location is critical in maintaining product quality. Establishing robust equivalence studies as part of the validation deliverables strengthens the ongoing review process.

5. Integrating Ongoing Review with Vendor Audits

Vendor audits are critical to assessing ongoing compliance with quality standards. Integrating review findings with audit processes optimizes oversight. This section outlines practical steps for integrating these two essential activities.

5.1 Audit Planning and Preparation

Conducting effective vendor audits requires meticulous planning and preparation. Consider the following steps:

• Define Objectives: Clearly outline the objectives of the audit, including specific areas of concern or previous CAPAs.
• Team Composition: Assemble a multidisciplinary audit team with expertise relevant to the specific supplier or CMO/CDMO under review.
• Audit Schedule: Develop a comprehensive schedule detailing the timeline and areas/categories to be audited.

5.2 Audit Execution and Reporting

During the audit, the focus should be on evaluating compliance with quality agreements, validation deliverables, and any previous findings. Detailed reporting, including strengths, weaknesses, and recommendations for corrective actions, is vital for effective follow-up and ongoing review adjustments.

6. Tech Transfer Packages and Their Role in Ongoing Review

Tech transfer packages are essential when moving processes from one facility to another. In the context of ongoing review, these packages ensure that product quality is maintained throughout the transfer process. This section explores the essential components of effective tech transfer packages.

6.1 Core Components of Tech Transfer Packages

Successful tech transfer requires comprehensive planning and documentation. The following components should be included:

• Process Documentation: Detailed descriptions of the manufacturing processes, equipment, and controls.
• Quality Standards: Specifying all quality-related requirements that must be met during the transfer.
• Validation Protocols: Including pre- and post-transfer validation protocols to assess compliance with product specifications.

6.2 Ongoing Review Post-Transfer

Once a tech transfer is completed, it is essential to initiate ongoing reviews to monitor performance against established quality metrics. This includes absorbing data from performance metrics, continued risk assessments, and establishing a feedback loop for continuous improvement.

7. Conclusion and Best Practices for Ongoing Review

In conclusion, establishing a thorough ongoing review process for inspections is a dynamic and pivotal requirement for pharmaceutical professionals. As part of a comprehensive oversight strategy of suppliers and CMOs/CDMOs, the ongoing review encompasses risk evaluation, supplier qualifications, validation deliverables, vendor audits, and tech transfer packages.

Best practices to ensure an effective ongoing review include:

• Data-Driven Approach: Utilizing historical performance data to inform ongoing assessments and risk evaluations.
• Regular Training: Ensuring all staff involved in vendor oversight and quality assurance are well-trained in current practices and regulations.
• Collaboration and Communication: Foster open lines of communication between internal and external stakeholders to facilitate timely information exchange and collaboration for problem-solving.

As the pharmaceutical landscape continues to evolve, adhering to these guidelines will help ensure that pharmaceutical companies meet their compliance obligations while prioritizing patient safety and product quality.